Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
Predictive Oncology (NASDAQ: POAI) announced significant advancements in ovarian cancer research through its subsidiary, TumorGenesis. Researchers utilized TumorGenesis’s media to study how ovarian cancer cells migrate, which could lead to targeted drug therapies aimed at blocking metastasis. This research highlights the potential for several billion dollars in future revenues for biotech companies. Additionally, the study identified a mechanism involving PARP inhibitors, which, when combined with PARGs, could improve patient outcomes. This research underscores the role of AI in personalized medicine and drug discovery.
- Significant advancements in ovarian cancer research may lead to targeted therapies.
- Potential for several billion dollars in future revenues for biotech and pharma companies.
- Identification of a new mechanism involving PARGs could enhance treatment efficacy.
- Current PARP inhibitors are subject to resistance, limiting their long-term effectiveness.
MINNEAPOLIS, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the products of its wholly owned subsidiary, TumorGenesis, aided researchers in the understanding of how ovarian cancer cells migrate outside the abdominal cavity. The research, completed by a top-tier laboratory in Massachusetts, used TumorGenesis’s media to capture, culture, and identify how these cells ‘break through’ the protective lining in the abdomen, called the omentum or abdominal membrane.
This discovery means that drugs could be targeted against that receptor site of the omentum or lining to effectively ‘block’ the metastasis of re-occurring ovarian cancer. Nearly
The second big breakthrough was done by another topflight researcher in the UK that used the media to isolate, identify and study a mechanism for treatment for some ovarian cancer patients. The treatment, a PARP inhibitor, inhibits the enzyme that in cancer cells repairs damaged DNA. This treatment sometimes accelerates the metastasis, often killing the patient.
By successfully growing the cell lines used for the treatment, the researchers found a defective enzyme that can be easily blocked by a class of compounds called PARGs (poly (ADP-ribose) glycohydrolase). If the enzymes are blocked, the patients treated are expected to then have a positive response to continued PARP-PARG treatment.
“Both targets of the research aided by TumorGenesis’s technology, blocking the omentum penetration and blocking the enzyme that accelerates a response to PARP treatment, once developed and approved, represent several billion dollars in future revenues for biotech or pharma companies. Three currently available PARP inhibitors, each becoming resistant to ovarian cancer over time, generate
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
Investor Relations Contact:
Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net
FAQ
What recent development has Predictive Oncology made regarding ovarian cancer?
How might TumorGenesis's research impact the treatment of ovarian cancer?
What is the significance of the PARP inhibitors research by TumorGenesis?
What are the statistics related to ovarian cancer mentioned in the press release?
Which subsidiary of Predictive Oncology is involved in this ovarian cancer research?
